Celldex Therapeutics, Inc - CLDX STOCK NEWS

Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023, at 11:30 am ET. The event will be accessible via a webcast on the company's website, with a replay available for 90 days post-event. Celldex is a clinical-stage biotechnology firm focusing on developing monoclonal and bispecific antibodies to treat severe diseases. Their innovative therapeutics aim to engage the immune system or target critical pathways, enhancing treatment options for patients with inflammatory diseases and various cancers.

Celldex Therapeutics (NASDAQ:CLDX) reported its financial results for Q4 and the full year 2022, showcasing notable advancements in its pipeline. The company highlighted positive data from its Phase 1b barzolvolimab study for chronic spontaneous urticaria (CSU), with significant symptom improvement rates reported. Phase 2 enrollment for CSU is expected to conclude by Q3 2023, with topline data anticipated late this year or early 2024. Celldex's financials show a net loss of $112.3 million for 2022, an increase from $70.5 million in 2021, primarily due to higher R&D expenses. The company maintains sufficient funds to support operations through 2025.

Celldex Therapeutics (NASDAQ:CLDX) presented promising Phase 1b clinical trial data for barzolvolimab, aimed at treating patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines. At week 12, 56% of patients on multiple doses achieved complete response, while 76% showed well-controlled disease. After 24 weeks, 53% maintained complete response. The drug exhibited a favorable safety profile, with most adverse events being mild or moderate. Barzolvolimab demonstrates potential as a best-in-class therapy in the limited treatment landscape for CSU, paving the way for ongoing Phase 2 trials.

Celldex Therapeutics (NASDAQ:CLDX) has appointed Dr. Rita Jain to its Board of Directors. Dr. Jain brings extensive experience in drug development, previously serving in executive roles at ChemoCentryx, Immunovant, and Akebia. According to CEO Anthony Marucci, her expertise will enhance the board's capabilities as the company advances its programs, particularly barzolvolimab, which aims to address various conditions in allergy and immunology. Dr. Jain expressed her excitement about joining the company during this critical phase. Celldex focuses on developing antibody-based therapeutics for serious diseases with significant unmet medical needs.

Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 9:20 am ET. This event will be available via webcast on their Investors & Media page, with a replay accessible for 90 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating severe diseases, including various cancers and inflammatory conditions. Their pipeline highlights antibody-based therapeutics that engage the human immune system to enhance patient outcomes.

Celldex Therapeutics (NASDAQ:CLDX) announced the presentation of data from its Phase 1b multi-dose study of barzolvolimab for chronic spontaneous urticaria at the AAAAI Annual Meeting 2023, occurring from February 24-27 in San Antonio, Texas. The presentation is scheduled for February 26th, showcasing data through 24 weeks for cohorts receiving varying dosages (0.5, 1.5, 3.0, and 4.5 mg/kg). New data will be highlighted, with the company hosting a live webcast on the same day at 4:00 pm CT. This study represents a critical step in the development of treatments targeting inflammatory diseases.

Celldex Therapeutics (NASDAQ:CLDX) recently shared promising results from its Phase 1b clinical trial of barzolvolimab, targeting chronic inducible urticaria. In this trial, all 9 patients with cold urticaria treated with a 1.5 mg/kg dose achieved a 100% response rate. The company also confirmed durable mast cell suppression and response in patients from previous cohorts treated at 3.0 mg/kg over an extended follow-up period. These findings were presented at the GA²LEN Global Urticaria Forum, reinforcing barzolvolimab's potential as an effective therapy for severe mast cell-driven diseases.

Celldex Therapeutics has announced presentations from its barzolvolimab development program at the 6th GA²LEN Global Urticaria Forum in Berlin, December 7-8, 2022. Key highlights include data from the Phase 1b cold urticaria cohorts at 1.5 mg/kg and 3.0 mg/kg. The first day features an oral presentation on cold urticaria responses to barzolvolimab. The second day features a poster on mast cell suppression and an encore oral presentation on chronic spontaneous urticaria effectiveness. A webcast conference call is scheduled for December 6 at 8:00 a.m. ET.